Skip to main content
ChemoMetec logo

ChemoMetec — Investor Relations & Filings

Ticker · CHEMM ISIN · DK0060055861 LEI · 213800533NBKECGONO68 CO Manufacturing
Open in API
Filings indexed 538 across all filing types
Latest filing 2022-02-08 Earnings Release
Country DK Denmark
Listing CO CHEMM

About ChemoMetec

https://chemometec.com

ChemoMetec is a global manufacturer specializing in high-precision automated cell counting and analysis instrumentation. The company develops and produces a range of advanced image cytometers and cell density analyzers, including the NucleoCounter® and XcytoMatic® series. These systems provide consistent, reproducible, and accurate cell count and viability data for a wide range of cell types. Key technologies include fluorescence microscopy, which enables trypan blue-free analysis, and specialized consumables designed to minimize human error. ChemoMetec's instruments are designed for regulated environments, offering software solutions compliant with FDA 21 CFR Part 11 and supporting Good Manufacturing Practice (GMP) workflows. The company serves customers in the biotechnology, pharmaceutical, and academic sectors, with applications in cell and gene therapy, cancer research, and bioprocessing.

Recent filings

Filing Released Lang Actions
Earnings Release 2022
Earnings Release Classification · 1% confidence The document provides key financial highlights for the first half (H1 2021/22), including revenue growth (DKK 209.8 million), EBITDA figures (DKK 115.9 million), and margin improvements. It discusses business segments (LCB) and market performance (North America). Crucially, the text ends with the statement: "The interim report for H1 2021/22 is attached to this announcement." This structure—a summary of period results followed by a reference to the full attached report—is characteristic of an Earnings Release (ER) or a Report Publication Announcement (RPA). Since the text contains detailed financial metrics and commentary on the period's performance, it functions primarily as an Earnings Release (ER). If the document were only the announcement stating the report was available, it would be RPA. Given the content is the core summary of the period's results, ER is the most appropriate classification, although RPA is a close secondary possibility based on the final sentence and short length (3782 chars). I will classify it as ER because it contains the actual results summary, not just a notice of publication. H1 2022
2022-02-08 English
Godt 1. halvår med en omsætningsvækst på 58% og en forbedret EBITDA-margin
Regulatory Filings
2022-02-08 Danish
Godt 1. halvår med en omsætningsvækst på 58% og en forbedret EBITDA-margin
Regulatory Filings
2022-02-08 Danish
Godt 1. halvår med en omsætningsvækst på 58% og en forbedret EBITDA-margin
Report Publication Announcement Classification · 1% confidence The document is a short announcement (3,874 characters) from ChemoMetec regarding their 1st half-year financial results. While it summarizes key financial highlights, the final paragraph explicitly states: 'Delårsrapporten for 1. halvår 2021/22 er vedhæftet som bilag til denne meddelelse' (The interim report for the 1st half of 2021/22 is attached as an appendix to this announcement). According to the 'Menu vs Meal' rule, since this is a short announcement of an attached report, it is classified as a Report Publication Announcement (RPA).
2022-02-08 Danish
Godt 1. halvår med en omsætningsvækst på 58% og en forbedret EBITDA-margin
Report Publication Announcement Classification · 1% confidence The document is a short announcement (under 5,000 characters) from ChemoMetec regarding their H1 2021/22 financial results. It explicitly states that the full interim report is attached as an appendix ('Delårsrapporten for 1. halvår 2021/22 er vedhæftet som bilag til denne meddelelse'). Following the 'Menu vs Meal' rule, this is an announcement of a report rather than the report itself, making it a Report Publication Announcement (RPA).
2022-02-08 Danish
Earnings Release 2022
Earnings Release Classification · 1% confidence The document is a short announcement dated January 28, 2022, titled 'Revenue and EBITDA guidance raised'. It explicitly states revised financial guidance (revenue and EBITDA) for the financial year 2021/22. This content aligns perfectly with an Earnings Release (ER), which is defined as the initial announcement of periodical financial results (key highlights only). It is not a full report (10-K or IR) nor a transcript (CT). H1 2022
2022-01-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.